COVID-19 Impact Analysis on Global Induced Pluripotent Stem Cells Market
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the global induced pluripotent stem cells market. In addition, complete analysis of changes on the global induced pluripotent stem cells market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The pandemic slackened the economic growth of various countries comprising the U.S., Germany, the UK, India and China. It also resulted in control measures which impacted operations in life science organizations such as production and research. In an article published by Nature Biotechnology, the CEO of flagship Pioneering stated that lab productivity at many of its research-based setup was running at just 30-50% capacity, and even upholding that rate was a challenge. More than 750 trials of cell and gene therapy in almost 30,000 patients were underway as of June 2020, and CGT products account for some 12% of the pharmaceutical industry’s clinical pipeline and at least 16% of its preclinical pipeline. As per the GEP Worldwide, more than 1,200 clinical trials worldwide were disrupted by June 2020. Nearly 61% of clinical trials were disrupted owing to the suspension of patient enrolment. The impact varied owing to changes in COVID-19 case volume throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory diseases, oncology, ID/anti-infectives and cardiovascular diseases were the worst-hit during this time.
Market Overview- Global Induced Pluripotent Stem Cells Market
The factors such as growing investment in basic level research, especially by research organizations and academic institutes in the last few years has led to an increased understanding of the fundamental pathways through which induced pluripotent stem cells market implicated in disease development are either up or down-regulated. This leads to more questions about how biology works, the cause of the diseases and potential diagnoses and treatments. Induced pluripotent stem cells display a particular gene expression signature that is similar to that of embryonic stem cells (ESCs) and exhibit both pluripotency and the capacity of self-renewal.
In the recent years, the complexity of products requested by researchers has grown and this suggests improvement in understanding of the basic pathways and discovery of some new pathways. It is important for manufacturers of research products to keep up with the latest developments to cater to the ever-changing requirements of the life sciences industry.
Despite the presence of several large-scale players as well as multiple regional companies in the global iPS cell market, there are very limited companies that have a complete focus on being a provider of life science reagents and products. Different manufacturers have different product offerings and specializations, with most large companies combining research products and reagents with equipment and in-vitro diagnostics tools. Having a sole focus on this market ensures better quality of products, customer loyalty and an established distribution network that can increase the availability of the product across the globe.
The spending by companies on the research and development pertaining to life sciences is expected to provide lucrative prospects for growth. Companies investing in providing tools and products to cater to the research requirements of several healthcare providers and research institutes can expect to see stable returns.
The major disadvantage associated with autologous stem cell transplants in cancer therapy is that cancer cells sometimes also get collected, along with stem cells, which may further put it back into the body during the therapy. These factors collectively likely to restrain the market growth during the forecast period.
Market Growth Challenges
The induced pluripotent stem cells market is anticipated to face challenges during the manufacturing. The certain challenges in manufacturing are transitioning manufacturing from small to large scale along with in-house vs. outsourced manufacturing, new and innovative ways to manufacture cell and gene therapy for the future, standards for new cell and gene therapy products, logistic challenges with cell therapy manufacturing and challenges with vector production. This are some challenges in manufacturing of induced pluripotent stem cells market which may limit the growth of induced pluripotent stem cells market.
Cumulative Growth Analysis
The report provides in-depth analysis of global induced pluripotent stem cells market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various iodine derivatives in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
Market Segmental Overview
The global induced pluripotent stem cells market comprises of different market segment like derived Cell Type, Product, Processes, Application, End User and Geography.
Induced Pluripotent Stem Cells Market by Derived Cell Types
The various derived cell types comprised in the reports are hepatocytes, fibroblasts, keratinocytes and amniotic cells. The hepatocytes segment is likely to dominate the market during the forecast period. Hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (iPSCs) hold great promise in toxicological applications as well as in regenerative medicine. Previous efforts on hepatocyte differentiation have mostly relied on the use of growth factors (GFs) to recapitulate developmental signals under in vitro conditions. Recently, the use of small molecules (SMs) has emerged as an attractive tool to induce cell fate transition due to its superiority in terms of both quality and cost. However, HLCs derived using SMs have not been well characterized, especially on the transcriptome level.
Induced Pluripotent Stem Cells Market by Product
The certain products comprised in the global induced pluripotent stem cells market are instruments/devices, automated platforms, consumables and kits and services. The instruments/devices segment is likely to dominate the market during the forecast period. The biopharma industry is continuing to adapt more cell-based assays for primary and secondary screening because of higher biological relevance and increased value of information. As part of this evolution, there is a desire to move from immortalized, stable cell lines to primary cells and stem cells. Stem cells offer the advantages of providing better clinical relevance of information compared to cell lines, being available in larger quantities, and having higher assay reproducibility than primary cells. Therefore, there is a great interest in automated stem cell assays to use as screening tools in early drug development, and to evaluate potential toxic effects of new compounds.
Induced Pluripotent Stem Cells Market by Processes
The various processes such as manual and automated are comprised in the induced pluripotent stem cells market. The automated manual segment is likely to dominate the market during the forecast period. The various factors such as ability to make any cell or tissue the body might need coupled with government and private sectors are sectors are increasing funding and rising industry that focuses on different research work.
Induced Pluripotent Stem Cells Market by Application
The different application of induced pluripotent stems cells comprised in the report are drug development and discovery, toxicity screening and regenerative medicines. The drug development and discovery segment is likely to dominate the market during the forecast period. Stem cells are fast becoming an invaluable tool in the drug discovery process. Stem cells offer the remarkable capacity to generate an unlimited source of disease relevant cell types from which to identify novel molecular targets, perform large-scale phenotypic screens and also identify off-target toxicities.
Induced Pluripotent Stem Cells Market by End User
The various end user comprised in the global induced pluripotent stem cells market are hospitals, research laboratories and academic research. The hospitals segment is likely to dominate the market during the forecast period. According to survey conducted by American Hospital Association, there are total, 6,090 hospitals across the United States. In which 5,141 are community hospitals, 208 federal government hospitals, 625 are non-federal psychiatric hospitals and 116 are other hospitals. The National Health Expenditure Accounts (NHEA) are the official estimates of total health care spending in the United States. Dating back of 1960, the NHEA measures annual U.S. expenditures for health care goods and services, public health activities, government administration, the net cost of health insurance, and investment related to health care. The data are presented by type of service, source of funding, and type of sponsor. The vast majority of eye care services in low- and middle-income countries are provided in secondary or tertiary hospitals, which are principally located in urban areas, adds to the inequity in access.
Induced Pluripotent Stem Cells Market by Geography
The regions such as North America, Europe, Asia Pacific and Rest of the World are comprised in the global induced pluripotent stem cells market. The North America is anticipated to dominate the market in 2021. Followed by Europe and the Asia Pacific. The large share of the North American market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells. The rising investment in pharmaceutical R&D is also boosting growth of cell and gene therapy manufacturing services market.
Competitive Landscape Analysis
The competitive landscape analysis of induced pluripotent stem cells market is certainly based range of market players operating in the healthcare market with increasing demand for production of induced pluripotent stem cells market. Besides, number of market players offered wide range of products for different application in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are Fujifilm Holding Corporation, Astellas Pharma Inc., Fate Therapeutics, Inc., Bristol-Myers Squibb Company, ViaCyte, Inc., Celgene Corporation, Aastrom Biosciences, Inc., Acelity Holdings, Inc., StemCells, Inc., Japan Tissue Engineering Co. Ltd. and Organogenesis Inc. among others.
June 2021: Thermo Fisher Scientific Inc. announced that it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company footprints in global market and leading to upsurge company growth in the upcoming years.
June 2020: The LumaCyte collaborated with Catalent who are the global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company stem cell technology product Radiance and its application.